128 related articles for article (PubMed ID: 38590011)
1. Prevalence of massively diluted bone marrow cell samples aspirated from patients with myelodysplastic syndromes (MDS) or suspected of MDS: A retrospective analysis of nationwide samples in Japan.
Ogata K; Mochimaru Y; Kasai N; Sei K; Kawahara N; Ogata M; Yamamoto Y
Br J Haematol; 2024 May; 204(5):1856-1861. PubMed ID: 38590011
[TBL] [Abstract][Full Text] [Related]
2. Revisiting the most often used item in the haematological tool box-The extent of haemodilution in bone marrow aspirates.
Hokland P
Br J Haematol; 2024 May; 204(5):1593-1594. PubMed ID: 38602310
[TBL] [Abstract][Full Text] [Related]
3. The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands.
Dinmohamed AG; van Norden Y; Visser O; Posthuma EF; Huijgens PC; Sonneveld P; van de Loosdrecht AA; Jongen-Lavrencic M
Leuk Res; 2015 Feb; 39(2):177-82. PubMed ID: 25533930
[TBL] [Abstract][Full Text] [Related]
4. [Re-evaluation of classification of myelodysplastic syndromes with low percentage bone marrow blasts].
Yu MH; Xu ZF; Li L; Nie L; Liu L; Zhang Y; Qin TJ; Hao YS; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2009 Jan; 30(1):3-7. PubMed ID: 19563026
[TBL] [Abstract][Full Text] [Related]
5. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
Bouscary D; De Vos J; Guesnu M; Jondeau K; Viguier F; Melle J; Picard F; Dreyfus F; Fontenay-Roupie M
Leukemia; 1997 Jun; 11(6):839-45. PubMed ID: 9177438
[TBL] [Abstract][Full Text] [Related]
6. "Bone marrow aspirate automated counts on hematology analyzers: formulating a scoring system based on hematology parameters, to discriminate reactive versus myelodysplastic syndrome-related bone marrows".
Tsagarakis NJ; Paterakis G; Papadhimitriou SI; Kritikou-Griva E; Goumakou E; Oudatzis G; Theodorakos I; Vasileiou P
Int J Lab Hematol; 2019 Aug; 41(4):542-549. PubMed ID: 31102331
[TBL] [Abstract][Full Text] [Related]
7. Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts.
Font P; Loscertales J; Soto C; Ricard P; Novas CM; Martín-Clavero E; López-Rubio M; Garcia-Alonso L; Callejas M; Bermejo A; Benavente C; Ballesteros M; Cedena T; Calbacho M; Urbina R; Villarrubia J; Gil S; Bellón JM; Diez-Martin JL; Villegas A
Ann Hematol; 2015 Apr; 94(4):565-73. PubMed ID: 25387664
[TBL] [Abstract][Full Text] [Related]
8. Prognostic relevance of histological findings on bone marrow biopsy in myelodysplastic syndromes.
Lambertenghi-Deliliers G; Annaloro C; Oriani A; Soligo D; Pozzoli E; Polli EE
Ann Hematol; 1993 Feb; 66(2):85-91. PubMed ID: 8448244
[TBL] [Abstract][Full Text] [Related]
9. [Clinically relevant possibilities and limits of differential diagnosis of megaloblastic anemia and myelodysplastic syndrome - refractory anemia type in bone marrow biopsies].
Vašeková P; Szépe P; Marcinek J; Balhárek T; Plank L
Vnitr Lek; 2016; 62(9):692-697. PubMed ID: 27715070
[TBL] [Abstract][Full Text] [Related]
10. Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes.
Arenillas L; Calvo X; Luño E; Senent L; Alonso E; Ramos F; Ardanaz MT; Pedro C; Tormo M; Marco V; Montoro J; Díez-Campelo M; Brunet S; Arrizabalaga B; Xicoy B; Andreu R; Bonanad S; Jerez A; Nomdedeu B; Ferrer A; Sanz GF; Florensa L
J Clin Oncol; 2016 Sep; 34(27):3284-92. PubMed ID: 27382099
[TBL] [Abstract][Full Text] [Related]
11. Differences in the bone marrow histology between childhood myelodysplastic syndrome with multilineage dysplasia and refractory cytopenia of childhood without multilineage dysplasia.
Iwafuchi H; Ito M
Histopathology; 2019 Jan; 74(2):239-247. PubMed ID: 30062702
[TBL] [Abstract][Full Text] [Related]
12. The proliferation index of specific bone marrow cell compartments from myelodysplastic syndromes is associated with the diagnostic and patient outcome.
Matarraz S; Teodosio C; Fernandez C; Albors M; Jara-Acevedo M; López A; Gonzalez-Gonzalez M; Gutierrez ML; Flores-Montero J; Cerveró C; Pizarro-Perea M; Paz Garrastazul M; Caballero G; Gutierrez O; Mendez GD; González-Silva M; Laranjeira P; Orfao A
PLoS One; 2012; 7(8):e44321. PubMed ID: 22952954
[TBL] [Abstract][Full Text] [Related]
13. Common and different alterations of bone marrow mesenchymal stromal cells in myelodysplastic syndrome and multiple myeloma.
Choi H; Kim Y; Kang D; Kwon A; Kim J; Min Kim J; Park SS; Kim YJ; Min CK; Kim M
Cell Prolif; 2020 May; 53(5):e12819. PubMed ID: 32372504
[TBL] [Abstract][Full Text] [Related]
14. High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS).
Mohamedali AM; Gäken J; Ahmed M; Malik F; Smith AE; Best S; Mian S; Gaymes T; Ireland R; Kulasekararaj AG; Mufti GJ
Leukemia; 2015 Sep; 29(9):1928-38. PubMed ID: 25943179
[TBL] [Abstract][Full Text] [Related]
15. Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome.
Mohamedali AM; Alkhatabi H; Kulasekararaj A; Shinde S; Mian S; Malik F; Smith AE; Gäken J; Mufti GJ
Blood; 2013 Jul; 122(4):567-70. PubMed ID: 23760614
[TBL] [Abstract][Full Text] [Related]
16. Will a peripheral blood (PB) sample yield the same diagnostic and prognostic cytogenetic data as the concomitant bone marrow (BM) in myelodysplasia?
Cherry AM; Slovak ML; Campbell LJ; Chun K; Eclache V; Haase D; Haferlach C; Hildebrandt B; Iqbal AM; Jhanwar SC; Ohyashiki K; Sole F; Vandenberghe P; VanDyke DL; Zhang Y; Dewald GW
Leuk Res; 2012 Jul; 36(7):832-40. PubMed ID: 22537394
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia.
Matsushima T; Handa H; Yokohama A; Nagasaki J; Koiso H; Kin Y; Tanaka Y; Sakura T; Tsukamoto N; Karasawa M; Itoh K; Hirabayashi H; Sawamura M; Shinonome S; Shimano S; Miyawaki S; Nojima Y; Murakami H
Blood; 2003 May; 101(9):3386-90. PubMed ID: 12506028
[TBL] [Abstract][Full Text] [Related]
18. Morphologic classification of the myelodysplastic syndromes (MDS): combined utilization of bone marrow aspirates and trephine biopsies.
Bartl R; Frisch B; Baumgart R
Leuk Res; 1992; 16(1):15-33. PubMed ID: 1732665
[TBL] [Abstract][Full Text] [Related]
19. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
20. Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients.
Matarraz S; López A; Barrena S; Fernandez C; Jensen E; Flores-Montero J; Rasillo A; Sayagues JM; Sánchez ML; Bárcena P; Hernandez-Rivas JM; Salvador C; Fernandez-Mosteirín N; Giralt M; Perdiguer L; Laranjeira P; Paiva A; Orfao A
Cytometry B Clin Cytom; 2010 May; 78(3):154-68. PubMed ID: 20198685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
